BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ishigami S, Arigami T, Setoyama T, Okumura H, Sasaki K, Uchikado Y, Kurahara H, Kijima Y, Nishizono Y, Nakajo A, Natsugoe S. Clinical–pathological implication of human leukocyte antigen-F–positive gastric adenocarcinoma. Journal of Surgical Research 2013;184:802-6. [DOI: 10.1016/j.jss.2013.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Manvailer LF, Wowk PF, Mattar SB, da Siva JS, da Graça Bicalho M, Roxo VM. HLA-F polymorphisms in a Euro-Brazilian population from Southern Brazil. Tissue Antigens 2014;84:554-9. [PMID: 25413105 DOI: 10.1111/tan.12444] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
2 Xu Y, Han H, Zhang F, Lv S, Li Z, Fang Z. Lesion human leukocyte antigen-F expression is associated with a poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2015;9:300-4. [PMID: 25435979 DOI: 10.3892/ol.2014.2686] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
3 Würfel FM, Winterhalter C, Trenkwalder P, Wirtz RM, Würfel W. European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment. Int J Mol Sci 2019;20:E1830. [PMID: 31013867 DOI: 10.3390/ijms20081830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Harada A, Ishigami S, Kijima Y, Nakajo A, Arigami T, Kurahara H, Kita Y, Yoshinaka H, Natsugoe S. Clinical implication of human leukocyte antigen ( HLA )‐ F expression in breast cancer. Pathol Int 2015;65:569-74. [DOI: 10.1111/pin.12343] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
5 Toni Ho G, Heinen F, Stieglitz F, Blasczyk R, Bade-döding C. Dynamic Interaction between Immune Escape Mechanism and HLA-Ib Regulation. In: Rezaei N, editor. Immunogenetics. IntechOpen; 2019. [DOI: 10.5772/intechopen.80731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
6 Hò GT, Heinen FJ, Huyton T, Blasczyk R, Bade-Döding C. HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues. Immunogenetics 2019;71:353-60. [PMID: 30941482 DOI: 10.1007/s00251-019-01112-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Giebel S, Boratyn-nowicka A, Karabon L, Jedynak A, Pamula-pilat J, Tecza K, Kula D, Kowal M, Frydecka I, Grzybowska E. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with epithelial ovarian cancer. Human Immunology 2014;75:508-13. [DOI: 10.1016/j.humimm.2014.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]